Evaluation of data from the Quantra Hemostasis Analyzer in multiple trauma patients to validate and optimize the existing therapy algorithm.

Evaluation of data from the Quantra Hemostasis Analyzer in multiple trauma patients to validate and optimize the existing therapy algorithm. - GHD (Golden Hour of Diagnostics)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027072

Enrollment

Registered

2022-03-07

Start date

2021-03-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple trauma/ polytrauma trauma-induced coagulopathy D65-D69

Interventions

Group 1: The first blood sample and analysis using the viscoelastic test method (VET) is usually carried out in the trauma room, others will follow as required during the operative care. For this purp

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients after severe blunt or penetrating trauma with active bleeding or an expected high risk of developing significant bleeding in the course of the disease.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The aim of the study is to evaluate data from the Quantra Hemostasis Analyzer in multiple trauma patients in order to validate and optimize the existing therapy algorithm. The first blood sample and analysis using the viscoelastic test method (VET) is usually carried out in the trauma room, others will follow as required during the operative care. For this purpose, an additional 3.2 ml of blood is taken from the patient in a standard coagulation tube (citrate tube) approx. 10 minutes after arrival via a venous or arterial puncture with the standard blood samples and analyzed directly in the Quantra Hemostasis Analyzer. The QStat® cassette is used for this. With the QStat® cassette, the extent and the start time of the fibrinolysis can be precisely monitored. In addition, changes in clot strength can be detected with and without the addition of tranexamic acid. With the help of the SEER (Sonic Estimation of Elasticity via Resonance) technology, the blood sample is vibrated by ultrasound and the linear elastic deformation as a result of the applied shear forces is measured. This not only measures the time required for coagulation, but also the mechanical properties of a clot.	—

Measure

Time frame

The aim of the study is to evaluate data from the Quantra Hemostasis Analyzer in multiple trauma patients in order to validate and optimize the existing therapy algorithm. The first blood sample and analysis using the viscoelastic test method (VET) is usually carried out in the trauma room, others will follow as required during the operative care. For this purpose, an additional 3.2 ml of blood is taken from the patient in a standard coagulation tube (citrate tube) approx. 10 minutes after arrival via a venous or arterial puncture with the standard blood samples and analyzed directly in the Quantra Hemostasis Analyzer. The QStat® cassette is used for this. With the QStat® cassette, the extent and the start time of the fibrinolysis can be precisely monitored. In addition, changes in clot strength can be detected with and without the addition of tranexamic acid. With the help of the SEER (Sonic Estimation of Elasticity via Resonance) technology, the blood sample is vibrated by ultrasound and the linear elastic deformation as a result of the applied shear forces is measured. This not only measures the time required for coagulation, but also the mechanical properties of a clot.

—

Secondary

Measure	Time frame
The collected data should be used to retrospectively determine whether an early statement can be made about the prognosis of the outcome of multiple trauma patients.	—

Countries

Germany

Contacts

Public ContactSara Kruse

Klinikum Bremen Mitte Unfallchirurgie

Sara.Kruse@gesundheitnord.de042149771225

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026